AusperBio Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 160

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $120M

  • Investors
  • 8

AusperBio General Information

Description

Manufacturer of oligonucleotide-based therapeutics focused on curing hepatitis B and treating a broad range of diseases through targeted delivery. The company specialises in liver-targeted delivery systems, metabolic disorder treatments, genetic disease therapies, immune modulation agents, preclinical validation models and structure-guided drug design tools, thereby improving treatment precision, reducing side effects and transforming patient outcomes.

Contact Information

Website
www.ausperbio.cn
Formerly Known As
Hangzhou Chengyuebo Pharmaceutical
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Floors 24-25, Building 5, Tianhe High-tech Industrial Park
  • Binjiang District
  • Hangzhou, Zhejiang 900000
  • China
+86 0571
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Manufacturing, Life Sciences, Oncology
Corporate Office
  • Floors 24-25, Building 5, Tianhe High-tech Industrial Park
  • Binjiang District
  • Hangzhou, Zhejiang 900000
  • China
+86 0571

AusperBio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AusperBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series C) 27-Aug-2026 $120M Completed Generating Revenue
6. Later Stage VC (Series B2) 04-Sep-2025 Completed Generating Revenue
5. Later Stage VC (Series B1) 24-Apr-2025 Completed Generating Revenue
4. Later Stage VC (Series B) 20-Dec-2024 Completed Generating Revenue
3. Early Stage VC (Series A) 02-Jul-2024 Completed Generating Revenue
2. Early Stage VC 14-Aug-2023 $13.9M $29.9M Completed Generating Revenue
1. Early Stage VC 13-Oct-2022 $16M $16M Completed Generating Revenue
To view AusperBio’s complete valuation and funding history, request access »

AusperBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Manufacturer of oligonucleotide-based therapeutics focused on curing hepatitis B and treating a broad range of diseases
Drug Discovery
Hangzhou, China
160 As of 2026

Vienna, Austria
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AusperBio Competitors (44)

One of AusperBio’s 44 competitors is Apeptico, a Formerly VC-backed company based in Vienna, Austria.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apeptico Formerly VC-backed Vienna, Austria
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
ENYO Pharma Venture Capital-Backed Lyon, France
Imcare Biotech Venture Capital-Backed Doylestown, PA
Galectin Therapeutics Corporation Norcross, GA
You’re viewing 5 of 44 competitors. Get the full list »

AusperBio Patents

  • 13

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 2

    Pending

  • Expiring in next 12 mo

AusperBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026200974-A1 Dosing regimens for hbv treatment Pending 25-Mar-2025
WO-2025242158-A1 Combination treatments Pending 22-May-2024
WO-2024221135-A1 Oligonucleotides for use in modulating immune responses against hepatitis b viral infection Inactive 23-Apr-2023
WO-2024222647-A1 Oligonucleotides for use in modulating immune responses against hepatitis b viral infection Inactive 23-Apr-2023
WO-2024149282-A1 Modified multi-segmented antisense oligonucleotides for use Inactive 10-Jan-2023 C12N15/1137
To view AusperBio’s complete patent history, request access »

AusperBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AusperBio Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
RA Capital Management Asset Manager Minority
CDH Investments PE/Buyout Minority
Sherpa Healthcare Partners Growth/Expansion Minority
Genesis Capital (Hong Kong) Growth/Expansion Minority
Hankang Capital Growth/Expansion Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

AusperBio FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process